Вирус иммунодефицита человека - медицина. Руководство для врачей / Под ред. Н.А. Белякова и А.Г.Рахмановой.- СПб.: Балтийский образовательный центр, 2010.- С. 183.

Balogou A.A., Saka B., Kombaté D., Kombaté K., Mouhari-Toure A., Akakpo S. Causes of mortality associated with HIV/AIDS in health-care facilities in Togo: a six-month prospective study // Trop. Doct.- 2011.- Vol. 41.- P. 215-217.

Sibéril S., Elluru S., Graff-Dubois S., Negi V.S., Delignat S., Mouthon L., Lacroix-Desmazes S., Kazatchkine M.D., Bayry J., Kaveri S.V. Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective // Ann. N Y Acad. Sci.- 2007.- Vol. 1110.- P. 497-506.

Asselman V., Thienemann F., Pepper D.J., Boulle A., Wilkinson R.J., Meintjes G. Central nervous system disorders after starting antiretroviral therapy in South Africa // AIDS.- 2010.- Vol. 24.- P. 2871-2876.

Howlett W.P. Neurological illness in HIV disease // Neurology in Africa.- 2012.- P. 191-206.

Bicanic T., Meintjes G., Rebe K., Williams A., Loyse A., Wood R. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study // J. Acquir. Immune Defic. Syndr.- 2009.- Vol. 51.- P. 130-134.

Магонов Е.П., Прахова Л.Н., Ильвес А. Г., Катаева Г.В., Трофимова Т.Н. Автоматическая сегментация МРТ-изображений головного мозга: методы и программное обеспечение // ВИЧ-инфекция и иммуносупрессии.- 2014.- Т. 6, № 3.- С. 73-77.

Letendre S.L., McCutchan J.A., Childers M.E., Woods S.P., Lazzaretto D., Heaton R.K., Grant I., Ellis R.J. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders // Annals of Neurology.- 2004.- Vol. 56.- P. 416-423.

Palmer S., Josefsson L., Coffin J.M. HIV reservoirs and the possibility of a cure for HIV-infection // Journal of internal medicine.- 2011.- Vol. 270.- P. 550-560.

Havlir D.V., Koelsch K.K., Strain M.C., Margot N., Lu B., Ignacio C.C., Miller M.D., Wong J.K.Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine pluseither tenofovir or stavudine // J. Infect. Dis. - 2005.- Vol. 191.- P. 1164-1168.

Maldarelli F., Palmer S., King M.S., Wiegand A., Polis M.A., Mican J., Kovacs J.A., Davey R.T., Rock-Kress D., Dewar R., Liu S., Metcalf J.A., Rehm C., Brun S.C., Hanna G.J., Kempf D.J., Coffin J.M., Mellors J.W.ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia // PLoS Pathog.- 2007.- Vol. 3.- P. 46-48.

Yukl S.A., Shergill A.K., McQuaid K., Gianella S., Lampiris H., Hare C.B., Pandori M., Sinclair E., Günthard H.F., Fischer M., Wong J.K., Havlir D.V. Effect of raltegravir-containing intensification on HIV burden and T-cell activation inmultiple gut sites of HIV-positive adults on suppressive antiretroviraltherapy // AIDS.- 2010.- Vol. 24.- Р. 2451-2460.

Palmer S., Josefsson L., Coffin J.M. HIV reservoirs and the possibility of acure for HIV infection // The Association for the Publication of the Journal of Internal Medicine.- 2011.- Vol. 270.- P. 550-560.

Berger M., McCallus D.E., Clindy S.L. Rapid and reversible responses to IVIG in autoimmune neuromuscular diseases suggest mechanisms of action involving competition with functionally important autoantibodies // J. Peripher. Nerv. Syst.- 2013.- Vol. 18.- P. 275-296.

Mantegazza R., Bonanno S., Camera G., Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis // Neuropsychiatr. Dis. Treat.- 2011.- Vol. 7.- P. 151-160.

Hughes R.A.C., Dalakas M.C., Cornblath D.R., Latov N., Weksler M.E., Relkin N. Clinical applications of intravenous immunoglobulins in neurology // Clin. Exp. Immunol.- 2009.- Vol. 158.- P. 34-42.

Melzer N., Meuth S.G. Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies // Clin. Exp. Immunol.- 2014.- Vol. 175.- P. 359-372.

Elovaam I., Apostolskib S., van Doornc P., Gilhusd N.E., Hietaharjue A., Honkaniemif J., van Schaikg I.N., Scoldingh N., Soelberg P., Uddj B. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases // European Journal of Neurology.- 2008.- Vol. 15.- P. 893-908.

Hartung H.P. Advances in the understanding of the mechanism of action of IVIg // J. Neurol.- 2008.- Vol. 255.- P. 3-6.

Ballow M. Mechanisms of immune regulation by IVIG // Curr. Opin. in Allergy and Clin. Immunol.- 2014.- Vol. 14.- P. 509-515.

Аверченков В.М., Палагин И.С. Внутривенные иммуноглобулины: механизмы действия и особенности клинического применения // Клиническая микробиология и антимикробная химиотерапия.- 2004.- № 6.- С. 273-281.

Ballow M. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in auto-immuen and inflammatory disorders // J. Allergy Clin. Immunol.- 2011.- Vol. 127.- P. 315-323.

Samuelsson A., Towers T.L., Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor // Science. - 2001.- Vol. 291.- P. 484-486.

Anthony R.M., Kobayashi T., Wermeling F., Ravetch J.V. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway // Nature.- 2011.- Vol. 475.- P. 110-113.

Lindkvist A., Edén A., Norström M.M., Gonzalez V.D., Nilsson S., Svennerholm B., Karlsson A.C., Sandberg J.K., Sönnerborg A., Gisslén M. Reduction of the HIV-1 reservoir inresting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-conceptstudy // AIDS Res. Ther.- 2009.- Vol. 6.- P. 15-17.

Cikurel K., Schiff L., Simpson D.M. Pilot Study of Intravenous Immunoglobulin in HIV-Associated Myelopathy // AIDS Patient Care and STDs.- 2009.- Vol. 23.- P. 75-78.

Di Rocco A., Simpson D.M. AIDS-associated vacuolar myelopathy // AIDS Patient Care and STDs.- 1998.- Vol. 12.- P. 457-461.

Petito C.K., Navia B.A., Cho E.S., Jordan B.D., George D.C., Price R.W. Vacuolar myelopathy pathologically resembling subacute combined degeneration in patients with the acquired immunodeficiency syndrome // New Engl. J. Med.- 1985.- Vol. 312.- P. 874-879.

Henin D., Smith T.W., De Girolami U., Sughayer M., Hauw J.J. Neuropathology of the spinal cord in the acquired immunodeficiency syndrome // Hum. Pathol.- 1992.- Vol. 23.- P. 1106-1114

Artigas J., Grosse G., Niedobitek F. Vacuolar myelopathy in AIDS: a morphologic analysis // Pathol. Res. Pract.- 1990.- Vol. 186.- P. 228-237.

Tan S.V., Guiloff R.J., Scaravilli F. AIDS-associated vacuolar myelopathy: a morphometric study // Brain.- 1991.- Vol. 118.- P. 1247-1261.

Fernàndez-Fernàndez F.J., de la Fuente-Aguado J., Ocampo-Hermida A., IglesiasCastanön A. Remission of HIV-associated myelopathy after highly active antiretroviral therapy // J. Postgrad. Med.- 2004.- Vol. 50.- P. 195-196.

Chong J., Di Rocco A., Tagliati M., Danisi F., Simpson D.M., Atlas S.W. MR Findings in AIDS-Associated Myelopathy // AJNR Am. J. Neuroradiol.- 1999.- Vol. 20.- P. 1412-1416.

Aboulafia D.M., Taylor L. Vacuolar myelopathy and vacuolar cerebellar leukoencephalopathy: A late complication of AIDS after highly active antiretroviral therapy-induced immune reconstitution // AIDS Patient Care and STDs.- 2002.- Vol. 12.- P. 579-584.

Staudinger R., Henry K.Remission of HIV myelopathy after highly active antiretroviral therapy // Neurology. - 2000.- Vol. 54.- P. 267-268.

Di Rocco A., Geraci A., Tagliati M. Remission of HIV myelopathy after highly active antiretroviral therapy // Neurology.- 2000.- Vol. 55.- P. 456.

Ramratnam B., Ribeiro R., He T., Chung C., Simon V., Vanderhoeven J., Hurley A., Zhang L., Perelson A.S., Ho D.D., Markowitz M. Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication // J. Acquir. Immune. Defic. Syndr.- 2004.- Vol. 35.- P. 33-37.